^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

36P - Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: a real-world multi-center study

Published date:
03/23/2023
Excerpt:
The more favorable PFS benefit demonstrated by first-line dabrafenib plus trametinib compared with all other therapy regimens indicates the optimal treatment choice for Chinese BRAF-mutated NSCLC patients.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A Retrospective Single-Center Study to Evaluate the Real-World Clinical Outcomes and Healthcare Resource Utilization in Chinese Patients with BRAF-Mutant Non-Small Cell Lung Cancer

Published date:
08/26/2022
Excerpt:
The study aims to explore the real-world clinical outcome and healthcare resource utilization of current treatment options in Chinese BRAF-mutated NSCLC patients in the first-line setting….Among the 44 patients, 8 patients with dabrafenib plus trametinib (D+T) had a higher objective response rate (75%) than other regimens...
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Spectrum of BRAF mutations in Indian patients with NSCLC: A molecular kaleidoscope

Published date:
05/19/2021
Excerpt:
...study of patients with BRAF mutated NSCLC...patient with a nonV600E mutation (V600_601delins, detected on NGS) received combination dabrafenib-trametinib with an ongoing partial response at 6 months.
DOI:
10.1200/JCO.2021.39.15_suppl.e21199